cortexolone 17α-valerate-21-propionate (CB-03-10) / Cosmo Pharma - LARVOL DELTA

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Cosmo Technologies Ltd | Active, not recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=90 | Active, not recruiting | Sponsor: Cosmo Technologies Ltd | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Mar 2023 ➔ Jun 2026 | Trial primary completion date: Nov 2022 ➔ Jan 2026

Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor